Study: NCT04643158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1402
Description: Randomised participants will receive oral inhalation of AZD1402, via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1402
Description: Randomised participants will receive oral inhalation of AZD1402, via DPI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised participants will receive oral inhalation of matching placebo via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short acting beta agonist (SABA) (rescue medication)
Description: In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short acting beta agonist (SABA) (rescue medication)
Description: In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Short acting beta agonist (SABA) (rescue medication)
Description: In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short acting beta agonist (SABA) (rescue medication)
Description: In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Run-in medications (ICS-LABA combination)
Description: During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Run-in medications (ICS-LABA combination)
Description: During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Run-in medications (ICS-LABA combination)
Description: During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Run-in medications (ICS-LABA combination)
Description: During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care.